JP6913968B2 - 前立腺がんの診断のための１８ｆ標識化合物およびその使用 - Google Patents

前立腺がんの診断のための１８ｆ標識化合物およびその使用 Download PDF

Info

Publication number
JP6913968B2
JP6913968B2 JP2019571446A JP2019571446A JP6913968B2 JP 6913968 B2 JP6913968 B2 JP 6913968B2 JP 2019571446 A JP2019571446 A JP 2019571446A JP 2019571446 A JP2019571446 A JP 2019571446A JP 6913968 B2 JP6913968 B2 JP 6913968B2
Authority
JP
Japan
Prior art keywords
compound
mmol
added
dissolved
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019571446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524175A (ja
JP2020524175A5 (https=
Inventor
ジ・デユン
イ・ビョンセ
チュ・ソヨン
ジョン・ウンジョン
ジョン・ヒョンジン
キム・ミンファン
キム・ミヒョン
イ・ギョチョル
イ・ヨンジン
パク・ジエ
ユ・ランジ
イム・サンム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Futurechem Co Ltd
Original Assignee
Futurechem Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Futurechem Co Ltd filed Critical Futurechem Co Ltd
Priority claimed from PCT/KR2018/006869 external-priority patent/WO2018236115A1/ko
Publication of JP2020524175A publication Critical patent/JP2020524175A/ja
Publication of JP2020524175A5 publication Critical patent/JP2020524175A5/ja
Application granted granted Critical
Publication of JP6913968B2 publication Critical patent/JP6913968B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019571446A 2017-06-19 2018-06-18 前立腺がんの診断のための１８ｆ標識化合物およびその使用 Active JP6913968B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2017-0077570 2017-06-19
KR20170077570 2017-06-19
KR1020180069590A KR102015355B1 (ko) 2017-06-19 2018-06-18 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도
KR10-2018-0069590 2018-06-18
PCT/KR2018/006869 WO2018236115A1 (ko) 2017-06-19 2018-06-18 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도

Publications (3)

Publication Number Publication Date
JP2020524175A JP2020524175A (ja) 2020-08-13
JP2020524175A5 JP2020524175A5 (https=) 2020-09-24
JP6913968B2 true JP6913968B2 (ja) 2021-08-04

Family

ID=65008286

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019571446A Active JP6913968B2 (ja) 2017-06-19 2018-06-18 前立腺がんの診断のための１８ｆ標識化合物およびその使用

Country Status (21)

Country Link
US (1) US10870629B2 (https=)
EP (1) EP3643707B1 (https=)
JP (1) JP6913968B2 (https=)
KR (1) KR102015355B1 (https=)
CN (1) CN110770212B (https=)
AU (1) AU2018288907B2 (https=)
CA (1) CA3067696C (https=)
CL (1) CL2019003727A1 (https=)
DK (1) DK3643707T3 (https=)
EA (1) EA037781B1 (https=)
ES (1) ES2912392T3 (https=)
HR (1) HRP20220557T1 (https=)
LT (1) LT3643707T (https=)
MX (1) MX388833B (https=)
MY (1) MY195426A (https=)
PH (1) PH12019502665A1 (https=)
PL (1) PL3643707T3 (https=)
PT (1) PT3643707T (https=)
RS (1) RS63205B1 (https=)
SG (1) SG11201911602RA (https=)
SI (1) SI3643707T1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494096C2 (ru) 2008-08-01 2013-09-27 Дзе Джонс Хопкинс Юниверсити Агенты, связывающиеся с psma, и их применение
WO2013022797A1 (en) * 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
WO2013028664A1 (en) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
JP2014051442A (ja) * 2012-09-05 2014-03-20 Kyoto Univ 前立腺がんを診断可能な核医学イメージングプローブ
EP3300746B1 (en) * 2013-01-14 2019-05-15 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
ES3005832T3 (en) 2013-11-13 2025-03-17 Ge Healthcare Ltd Dual run cassette for the synthesis of 18f-labelled compounds
KR20150113801A (ko) * 2014-03-31 2015-10-08 한미약품 주식회사 Tak1 저해 활성을 갖는 피라진 접합고리 유도체
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
WO2017027870A1 (en) * 2015-08-13 2017-02-16 The Johns Hopkins University Triazole conjugated ureas, thioureas, carbamates, and "reversed" carbamates for psma-targeted imaging agents and uses thereof
EP3493856B1 (en) 2016-06-28 2023-08-09 Cornell University 18f-labeled triazole containing psma inhibitors

Also Published As

Publication number Publication date
CN110770212B (zh) 2022-11-22
DK3643707T3 (da) 2022-05-09
JP2020524175A (ja) 2020-08-13
EP3643707A4 (en) 2021-06-09
RS63205B1 (sr) 2022-06-30
US10870629B2 (en) 2020-12-22
PT3643707T (pt) 2022-05-04
CA3067696A1 (en) 2018-12-27
EA202090071A1 (ru) 2020-04-16
AU2018288907B2 (en) 2020-05-07
AU2018288907A1 (en) 2020-01-23
SI3643707T1 (sl) 2022-06-30
CA3067696C (en) 2022-05-03
HRP20220557T1 (hr) 2022-06-10
KR102015355B1 (ko) 2019-10-23
CL2019003727A1 (es) 2020-07-03
EP3643707B1 (en) 2022-02-23
US20200207724A1 (en) 2020-07-02
CN110770212A (zh) 2020-02-07
SG11201911602RA (en) 2020-01-30
KR20180138169A (ko) 2018-12-28
MY195426A (en) 2023-01-20
EA037781B1 (ru) 2021-05-20
MX388833B (es) 2025-03-12
PH12019502665A1 (en) 2020-10-26
ES2912392T3 (es) 2022-05-25
BR112019027183A2 (pt) 2020-06-30
PL3643707T3 (pl) 2023-06-12
EP3643707A1 (en) 2020-04-29
LT3643707T (lt) 2022-05-25
MX2019015616A (es) 2020-02-26

Similar Documents

Publication Publication Date Title
ES2700234T3 (es) Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes
CA2924360C (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3375787B1 (en) Peptide thiourea derivative, radioisotope labeled compound containing same, and pharmaceutical composition containing same as active ingredient for treating or diagnosing prostate cancer
Hoigebazar et al. Synthesis and characterization of nitroimidazole derivatives for 68Ga-labeling and testing in tumor xenografted mice
Wang et al. Synthesis of a new bifunctional NODA for bioconjugation with PSMA ligand and one-step Al18F labeling
Roxin et al. Preliminary evaluation of 18F-labeled LLP2A-trifluoroborate conjugates as VLA-4 (α4β1 integrin) specific radiotracers for PET imaging of melanoma
WO2007122488A2 (en) Radiofluorinated compounds and their preparation
JP6913968B2 (ja) 前立腺がんの診断のための１８ｆ標識化合物およびその使用
JP2020524175A5 (https=)
PL239934B1 (pl) Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty
US10434196B2 (en) Multivalent saccharide complex, radioactive multivalent saccharide complex contrast agent, and use thereof
KR101375639B1 (ko) 아미노시클로펜탄카르복실산-함유 시클로 ｒｇｄ 유도체, 그 제조방법 및 그것을 포함하는 ｐｅｔ 조영제
KR20250127541A (ko) 방사성 동위원소가 표지된 할로겐화 벤즈아마이드 유도체 화합물을 유효성분으로 포함하는 암의 진단 또는 치료용 조성물
EA047774B1 (ru) Радиофармацевтический препарат для диагностики рака предстательной железы методом позитронной эмиссионной томографии и способ его получения
CN121021515A (zh) 靶向mat2a的化合物及其应用
BR112019027183B1 (pt) Composição farmacêutica para tratar ou diagnosticar câncer de próstata, radiofármaco para diagnóstico por imageamento de câncer de próstata
JPH07285888A (ja) アルキレンジアミン四酢酸誘導体とその 放射能標識化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210625

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210706

R150 Certificate of patent or registration of utility model

Ref document number: 6913968

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250